{'output': [['Allergan Plc', 'COMP', 'Forecast', '2018 Revenue Below Analystsâ€™ Estimates', 'ECON_INDICATOR'], ['Allergan Plc', 'COMP', 'Hurt', 'Loss of Market Exclusivity of Its Products', 'CONCEPT'], ['Allergan Plc', 'COMP', 'Plan', 'Sell Its Remaining Stake in Teva', 'COMP'], ['Allergan Plc', 'COMP', 'Record', 'Tax Benefit of $3.5 Billion to $4 Billion', 'ECON_INDICATOR', 'Relate_To', 'U.S. Tax Reform', 'CONCEPT'], ['Allergan Plc', 'COMP', 'Operate_In', 'San Francisco', 'GPE'], ['Allergan Plc', 'COMP', 'Expect', 'Total Net Revenue of $15.0 Billion-$15.3 Billion for Full-Year 2018', 'ECON_INDICATOR'], ['Allergan Plc', 'COMP', 'Does Not Expect', 'Any Generic Copies of Its Eye Drug Restasis Before the Second Quarter of 2018', 'CONCEPT'], ['Botox-maker', 'COMP', 'Provided the Updates', 'At the J.P. Morgan Healthcare Conference', 'EVENT']]}